LexAurum Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

LexAurum Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,801	Closed	-$132K	–	244
2019 Q4	$132K	Hold	5,801	–	–	0.07%	200
2019 Q3	$83K	Hold	5,801	–	–	0.05%	182
2019 Q2	$77K	Hold	5,801	–	–	0.05%	167
2019 Q1	$101K	Hold	5,801	–	–	0.07%	163
2018 Q4	$79K	Hold	5,801	–	–	0.06%	145
2018 Q3	$125K	Hold	5,801	–	–	0.09%	154
2018 Q2	$249K	Hold	5,801	–	–	0.22%	107
2018 Q1	$379K	Hold	5,801	–	–	0.32%	82
2017 Q4	$448K	Buy	+5,801	New	+$480K	0.42%	73

Other funds holding LUMO

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

IFG

Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LexAurum Advisors's LUMO Position: Q1 2020 in Review

LexAurum Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 5,801 shares — an estimated $132K sold.

LexAurum Advisors first reported a position in LUMO in Q4 2017 and held it in 9 quarters. The position peaked at $448K in Q4 2017. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

LexAurum Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
LexAurum Advisors sold 5,801 Lumos Pharma, Inc. Common Stock shares in Q1 2020, an estimated $132K.
LexAurum Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
LexAurum Advisors's Lumos Pharma, Inc. Common Stock position peaked at $448K in Q4 2017.
46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on LexAurum Advisors's 13F filing for Q1 2020, filed 22 Apr 2020.